Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • CDSCO to finalise new...

    CDSCO to finalise new clinical trial rules in two months

    Written by Ruby Khatun Khatun Published On 2018-06-02T09:30:03+05:30  |  Updated On 2 Jun 2018 9:30 AM IST
    CDSCO to finalise new clinical trial rules in two months

    MUMBAI: India's drug regulator plans to finalize new rules for clinical trials in a couple of months that would shorten the review time, a senior official said on Wednesday, aiming to boost clinical research in the country after interest in recent years waned.


    The country's 1.2 billion people and a large burden of diseases make for an attractive patient pool for global pharmaceutical companies looking to test new drugs, but stringent rules in the last few years have caused some companies to move their research work to other countries.


    New rules drafted by India's Central Drug Standard Control Organisation (CDSCO) aim to change that, reducing the approval time for review of applications to between 30 and 60 days, Ranga Chandrashekhar, a deputy drugs controller at the CDSCO said on the sidelines of a pharmaceutical conference in Mumbai.


    "We have already received comment from stakeholders on our draft, and it should be finalized in about two months," Chandrashekhar said.


    The draft was uploaded on the agency's website in February. If finalized, it would go to the country's health ministry for approval before being published, he added.


    The agency tightened rules for clinical research a few years ago after cases emerged of some patients being enrolled into trials without informed consent, and not being adequately compensated.


    The new rules would let the 'ethics committees' - groups of medical experts - that oversee clinical trials decide on the level of compensation for patients who suffer adverse events, Chandrashekhar said.


    Tougher compensation rules could turn the industry away from conducting trials at a time when companies have been gradually looking back to India for clinical work, warned D.G. Shah, secretary general of the Indian Pharmaceutical Alliance, which represents large Indian drugmakers.


    "There has been some revival (of clinical research) based on some assurances given by the government and simplifications (of rules)," Shah said. But if compensation rules are adopted as mentioned in the draft released by the CDSCO, companies "will run away from here," he said.


    "This is not conducive to doing innovation and research in India," Shah said.


    As part of overhauling drug regulations in the country, the CDSCO is also planning to bring in new rules for the sale of over-the-counter drugs, and e-pharmacies in the coming months, Chandrashekhar said.


    (Reporting by Zeba Siddiqui in Mumbai; Editing by Mark Potter)

    CDSCOCentral Drug Standard Control Organisationclinical researchcompensationDG Shahe-pharmaciesfinaliseGlobal pharmaceutical companiesIndian Pharmaceutical Alliancenew clinical trial rulesOver the counter drugsRanga Chandrashekhar
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok